To Evaluate the Safety of Duloxetine in Patients With Stress Urinary Incontinence
- Conditions
- Stress Urinary Incontinence
- Registration Number
- NCT00190645
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
The patients are being followed in this study to determine the safety of taking the medication Duloxetine for a long period of time. The patients participating in this study suffer from Stress Urinary Incontinence.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 600
Successfully completed the protocol for Study F1J-MC-SBAV.
Treatment with a drug, not including study medication, that has not received regulatory approval at the time of study entry.
Use of excluded medications within 14 days prior to study entry or at any time during the study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method To generate long-term safety data for duloxetine in the treatment of women with stress urinary incontinence(SUI).
- Secondary Outcome Measures
Name Time Method To collect data to demonstrate the maintenance of effect of duloxetine as measured by Patient Global Impression of Improvement (PGI-I) questionnaire.
Trial Locations
- Locations (2)
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician
🇺🇸Denver, Colorado, United States
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559,1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician
🇨🇦Oakville, Ontario, Canada